^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    BPB-101

    i
    Other names: BPB-101
    Associations

    News

    Trials
    Company:
    Betta Pharma
    Drug class:
    PD-L1 inhibitor, TGFβ inhibitor, GARP-TGFβ complex inhibitor
    Related drugs:
    Associations

    News

    Trials
    12ms
    Discovery and preclinical evaluation of BPB-101: a novel triple functional bispecific antibody targeting GARP-TGF-β complex/SLC, free TGF-β and PD-L1. (PubMed, Front Immunol)
    Furthermore, BPB-101 showed a favorable safety profile in nonhuman primate (NHP) toxicity studies. BPB-101 is a potentially promising therapeutic candidate that may address unmet clinical needs in cancer immunotherapy, thus, BPB-101 warrants further clinical investigation.
    Preclinical • Journal • PD(L)-1 Biomarker • IO biomarker
    |
    TGFB1 (Transforming Growth Factor Beta 1)
    |
    BPB-101
    over2years
    BPB-101 in Subjects With Metastatic or Locally Advanced Solid Tumors (clinicaltrials.gov)
    P1/2, N=388, Recruiting, Betta Pharmaceuticals Co., Ltd. | Not yet recruiting --> Recruiting
    Enrollment open • Metastases
    |
    BPB-101
    over2years
    BPB-101 in Subjects With Metastatic or Locally Advanced Solid Tumors (clinicaltrials.gov)
    P1/2, N=388, Not yet recruiting, Betta Pharmaceuticals Co., Ltd.
    New P1/2 trial • Metastases
    |
    BPB-101